Publications 2024

Grindedal EM, Zucknick M, Stormorken A, Rønne E, Tandstad NM, Isaacs WB, Axcrona K, Mæhle L (2024)
Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
Prostate (in press)
DOI 10.1002/pros.24711, PubMed 38629217

Skotheim RI, Bogaard M, Carm KT, Axcrona U, Axcrona K (2024)
Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature
Biochim Biophys Acta Rev Cancer, 1879 (2), 189080
DOI 10.1016/j.bbcan.2024.189080, PubMed 38272101

Publications 2023

Bogaard M, Skotheim RI, Maltau AV, Kidd SG, Lothe RA, Axcrona K, Axcrona U (2023)
'High proliferative cribriform prostate cancer' defines a patient subgroup with an inferior prognosis
Histopathology, 83 (6), 853-869
DOI 10.1111/his.15012, PubMed 37501635

Publications 2022

Axcrona K, Löffeler S (2022)
A Norwegian perspective on the Swedish national guidelines on prostate cancer for non-metastatic disease
Scand J Urol, 56 (4), 274-276
DOI 10.1080/21681805.2022.2075923, PubMed 35811479

Axcrona K, Aas K, Axcrona U, Skotheim RI (2022)
Re: Spatially Resolved Clonal Copy Number Alterations in Benign and Malignant Tissue
Eur Urol, 83 (2), 183
DOI 10.1016/j.eururo.2022.11.013, PubMed 36464529

Bjerknes C, Framroze B, Currie C, Pettersen CHH, Axcrona K, Hermansen E (2022)
Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis
Mar Drugs, 20 (4)
DOI 10.3390/md20040228, PubMed 35447901

Carm KT, Johannessen B, Bogaard M, Bakken AC, Maltau AV, Hoff AM, Axcrona U, Axcrona K, Lothe RA, Skotheim RI (2022)
Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer
Int J Cancer, 152 (5), 945-951
DOI 10.1002/ijc.34226, PubMed 35880692

Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M, Croyle JA, Noorzad Z, Calagua C, MacDonald TY, Axcrona U, Bogaard M, Axcrona K, Scherr DS, Sanda MG, Johannessen B, Chinnaiyan AM, Elemento O, Skotheim RI, Rubin MA, Barbieri CE et al. (2022)
Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci
JCI Insight, 7 (4)
DOI 10.1172/jci.insight.155309, PubMed 35050902

Kidd SG, Bogaard M, Carm KT, Bakken AC, Maltau AMV, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI (2022)
In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis
Mol Oncol, 16 (15), 2810-2822
DOI 10.1002/1878-0261.13225, PubMed 35574900

Skotheim RI, Axcrona U, Axcrona K (2022)
Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer
Eur Urol, 81 (4), 431
DOI 10.1016/j.eururo.2021.12.031, PubMed 35031159

Strømme JM, Johannessen B, Kidd SG, Bogaard M, Carm KT, Zhang X, Sveen A, Mathelier A, Lothe RA, Axcrona U, Axcrona K, Skotheim RI (2022)
Expressed prognostic biomarkers for primary prostate cancer independent of multifocality and transcriptome heterogeneity
Cancer Gene Ther, 29 (8-9), 1276-1284
DOI 10.1038/s41417-022-00444-7, PubMed 35194199

Publications 2021

Andreassen BK, Hektoen HH, Axcrona K, Langseth H, Stenehjem JS, Robsahm TE (2021)
Prediagnostic Serum-25 Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort: Answer to a Short Comment [Response to Letter]
Clin Epidemiol, 13, 1061-1062
DOI 10.2147/CLEP.S345565, PubMed 34803404

Bancroft EK, Page EC, Brook MN, Thomas S, Taylor N, Pope J, McHugh J, Jones AB, Karlsson Q, Merson S, Ong KR, Hoffman J, Huber C, Maehle L, Grindedal EM, Stormorken A, Evans DG, Rothwell J, Lalloo F, Brady AF, Bartlett M, Snape K, Hanson H, James P, McKinley J et al. (2021)
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
Lancet Oncol, 22 (11), 1618-1631
DOI 10.1016/S1470-2045(21)00522-2, PubMed 34678156

Hektoen HH, Gislefoss RE, Stenehjem JS, Langseth H, Axcrona K, Mondul AM, Robsahm TE, Andreassen BK (2021)
Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort
Clin Epidemiol, 13, 801-811
DOI 10.2147/CLEP.S319620, PubMed 34548821

Hektoen HH, Robsahm TE, Stenehjem JS, Axcrona K, Babigumira R, Mondul AM, Gislefoss RE, Andreassen BK (2021)
Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort
Cancer Med, 10 (12), 4107-4116
DOI 10.1002/cam4.3960, PubMed 34080787

Kidd SG, Carm KT, Bogaard M, Olsen LG, Bakken AC, Løvf M, Lothe RA, Axcrona K, Axcrona U, Skotheim RI (2021)
High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity
Neoplasia, 23 (6), 634-641
DOI 10.1016/j.neo.2021.05.012, PubMed 34107378

Tryggestad AMA, Axcrona K, Axcrona U, Bigalke I, Brennhovd B, Inderberg EM, Hønnåshagen TK, Skoge LJ, Solum G, Saebøe-Larssen S, Josefsen D, Olaussen RW, Aamdal S, Skotheim RI, Myklebust TÅ, Schendel DJ, Lilleby W, Dueland S, Kvalheim G (2021)
Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
Prostate, 82 (2), 245-253
DOI 10.1002/pros.24267, PubMed 34762317

Publications 2020

Dahl AA, Brennhovd B, Fosså SD, Axcrona K (2020)
A cross-sectional study of current work ability after radical prostatectomy
BMC Urol, 20 (1), 9
DOI 10.1186/s12894-020-0579-9, PubMed 32005115

Dahl AA, Fosså SD, Brennhovd B, Axcrona K (2020)
The EPIC-26 domain scores after radical prostatectomy are associated with the personality trait of neuroticism
Int Urol Nephrol, 53 (4), 691-698
DOI 10.1007/s11255-020-02688-4, PubMed 33118115

Hektoen HH, Robsahm TE, Andreassen BK, Stenehjem JS, Axcrona K, Mondul A, Gislefoss RE (2020)
Lifestyle associated factors and risk of urinary bladder cancer: A prospective cohort study from Norway
Cancer Med, 9 (12), 4420-4432
DOI 10.1002/cam4.3060, PubMed 32319230

Publications 2019

Carm KT, Hoff AM, Bakken AC, Axcrona U, Axcrona K, Lothe RA, Skotheim RI, Løvf M (2019)
Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer
Sci Rep, 9 (1), 13579
DOI 10.1038/s41598-019-49964-7, PubMed 31537872

Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS et al. (2019)
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
Eur Urol, 76 (6), 831-842
DOI 10.1016/j.eururo.2019.08.019, PubMed 31537406

Publications 2018

Gislefoss RE, Stenehjem JS, Hektoen HH, Andreassen BK, Langseth H, Axcrona K, Weiderpass E, Mondul A, Robsahm TE (2018)
Vitamin D, obesity and leptin in relation to bladder cancer incidence and survival: prospective protocol study
BMJ Open, 8 (3), e019309
DOI 10.1136/bmjopen-2017-019309, PubMed 29602840

Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2018)
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
Eur Urol, 75 (3), 498-505
DOI 10.1016/j.eururo.2018.08.009, PubMed 30181068

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W et al. (2018)
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition
Br J Cancer, 118 (6), e17
DOI 10.1038/bjc.2018.11, PubMed 29509747

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W et al. (2018)
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition
Br J Cancer, 118 (2), 266-276
DOI 10.1038/bjc.2017.429, PubMed 29301143

Publications 2017

Axcrona K, Nilsson R, Brennhovd B, Sørebø Ø, Fosså SD, Dahl AA (2017)
Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations
BMC Urol, 17 (1), 111
DOI 10.1186/s12894-017-0302-7, PubMed 29197360

Chen H, Ewing CM, Zheng S, Grindedaal EM, Cooney KA, Wiley K, Djurovic S, Andreassen OA, Axcrona K, Mills IG, Xu J, Maehle L, Fosså SD, Isaacs WB (2017)
Genetic factors influencing prostate cancer risk in Norwegian men
Prostate, 78 (3), 186-192
DOI 10.1002/pros.23453, PubMed 29181843

Li X, Zhong Y, Lu J, Axcrona K, Eide L, Syljuåsen RG, Peng Q, Wang J, Zhang H, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
Correction: MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
Oncotarget, 8 (4), 7208-7213
DOI 10.18632/oncotarget.14800, PubMed 28179591

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2017)
Intraductal Carcinoma of the Prostate on Diagnostic Needle Biopsy Predicts Prostate Cancer Mortality: A Population-Based Study
Prostate, 77 (8), 859-865
DOI 10.1002/pros.23326, PubMed 28240424

Aas K, Axcrona K, Kvåle R, Møller B, Myklebust TÅ, Axcrona U, Berge V, Fosså SD (2017)
Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway
Urology, 110, 140-147
DOI 10.1016/j.urology.2017.07.048, PubMed 28823634

Publications 2016

Li X, Zhong Y, Lu J, Axcrona K, Eide L, Syljuåsen RG, Peng Q, Wang J, Zhang H, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2016)
MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features
Oncotarget, 7 (26), 40297-40313
DOI 10.18632/oncotarget.9610, PubMed 27248169

Paur I, Lilleby W, Bøhn SK, Hulander E, Klein W, Vlatkovic L, Axcrona K, Bolstad N, Bjøro T, Laake P, Taskén KA, Svindland A, Eri LM, Brennhovd B, Carlsen MH, Fosså SD, Smeland SS, Karlsen AS, Blomhoff R (2016)
Tomato-based randomized controlled trial in prostate cancer patients: Effect on PSA
Clin Nutr, 36 (3), 672-679
DOI 10.1016/j.clnu.2016.06.014, PubMed 27406859

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2016)
Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality
Prostate, 76 (12), 1088-94
DOI 10.1002/pros.23192, PubMed 27271973

Østby-Deglum M, Axcrona K, Brennhovd B, Dahl AA (2016)
Ability to Reach Orgasm in Patients With Prostate Cancer Treated With Robot-assisted Laparoscopic Prostatectomy
Urology, 92, 38-43
DOI 10.1016/j.urology.2015.11.066, PubMed 26972145

Publications 2015

Saeter T, Bogaard M, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2015)
The relationship between perineural invasion, tumor grade, reactive stroma and prostate cancer-specific mortality: A clinicopathologic study on a population-based cohort
Prostate, 76 (2), 207-14
DOI 10.1002/pros.23112, PubMed 26477789

Saeter T, Vlatkovic L, Waaler G, Servoll E, Nesland JM, Axcrona K, Axcrona U (2015)
The prognostic value of reactive stroma on prostate needle biopsy: a population-based study
Prostate, 75 (6), 662-71
DOI 10.1002/pros.22957, PubMed 25620661

Østby-Deglum M, Brennhovd B, Axcrona K, Fosså SD, Dahl AA (2015)
A comparative study of erectile function and use of erectile aids in high-risk prostate cancer patients after robot-assisted laparoscopic prostatectomy
Scand J Urol, 49 (6), 433-439
DOI 10.3109/21681805.2015.1042038, PubMed 26116048

Publications 2014

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A et al. (2014)
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study
Eur Urol, 66 (3), 489-99
DOI 10.1016/j.eururo.2014.01.003, PubMed 24484606

Jakobsen JK, Krarup KP, Kirrander P, Håkansson U, Kaipia A, Perttila I, Axcrona K, Torkelsen TK, Hilmarsson R, Jensen JB, Scandinavian Penile Cancer Group (SCAPECA) (2014)
Penile cancer in Scandinavia: Current practice and future perspectives
Scand J Urol, 50 (1), 90-2
DOI 10.3109/21681805.2014.987316, PubMed 25438987

Ragnum HB, Vlatkovic L, Lie AK, Axcrona K, Julin CH, Frikstad KM, Hole KH, Seierstad T, Lyng H (2014)
The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
Br J Cancer, 112 (2), 382-90
DOI 10.1038/bjc.2014.604, PubMed 25461803

Servoll E, Sæter T, Vlatkovic L, Nesland JM, Waaler G, Axcrona K (2014)
Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience
Scand J Urol, 49 (3), 218-23
DOI 10.3109/21681805.2014.982168, PubMed 25428750

Servoll E, Vlatkovic L, Sæter T, Nesland JM, Axcrona U, Waaler G, Axcrona K (2014)
The length of a positive surgical margin is of prognostic significance in patients with clinically localized prostate cancer treated with radical prostatectomy
Urol Int, 93 (3), 289-95
DOI 10.1159/000362342, PubMed 25170745

Publications 2013

Brennhovd B, Axcrona K, Fosså SD, Giercksky KE, Vlatkovic L, Dahl AA (2013)
Robot-assisted radical prostatectomy of clinical high-risk patients with prostate cancer: a controlled study of operative and short-term postoperative events
Scand J Urol, 47 (6), 449-55
DOI 10.3109/21681805.2013.780257, PubMed 24328733

Liu Y, Sæter T, Vlatkovic L, Servoll E, Waaler G, Axcrona U, Giercksky KE, Nesland JM, Suo ZH, Axcrona K (2013)
Dendritic and lymphocytic cell infiltration in prostate carcinoma
Histol Histopathol, 28 (12), 1621-8
DOI 10.14670/HH-28.1621, PubMed 23729368

Liu Y, Wu X, Li X, Kvalheim G, Axcrona U, Axcrona K, Suo Z (2013)
Blocking mtDNA replication upregulates the expression of stemness-related genes in prostate cancer cell lines
Ultrastruct Pathol, 37 (4), 258-66
DOI 10.3109/01913123.2013.770112, PubMed 23634795

Ma Y, Liang D, Liu J, Wen JG, Servoll E, Waaler G, Sæter T, Axcrona K, Vlatkovic L, Axcrona U, Paus E, Yang Y, Zhang Z, Kvalheim G, Nesland JM, Suo Z (2013)
SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas
PLoS One, 8 (7), e70558 (Retracted)
DOI 10.1371/journal.pone.0070558, PubMed 23936228

Publications 2012

Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P (2012)
Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide
BJU Int, 110 (11), 1721-8
DOI 10.1111/j.1464-410X.2012.11107.x, PubMed 22500884

Hole KH, Axcrona K, Lie AK, Vlatkovic L, Geier OM, Brennhovd B, Knutstad K, Olsen DR, Seierstad T (2012)
Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance
Eur Radiol, 23 (4), 1158-66
DOI 10.1007/s00330-012-2669-x, PubMed 23114883

Liu Y, Vlatkovic L, Sæter T, Servoll E, Waaler G, Nesland JM, Giercksky KE, Axcrona K (2012)
Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
Int J Urol, 19 (8), 749-56
DOI 10.1111/j.1442-2042.2012.03017.x, PubMed 22487487

Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Giercksky KE, Nesland JM, Suo Z (2012)
Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines
Tumour Biol, 33 (4), 967-78
DOI 10.1007/s13277-012-0325-3, PubMed 22252524

Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE (2012)
Androgen deprivation therapy: past, present and future
BJU Int, 109 Suppl 6, 1-12
DOI 10.1111/j.1464-410X.2012.11215.x, PubMed 22672120

Steinsvik EA, Axcrona K, Angelsen A, Beisland C, Dahl A, Eri LM, Haug ES, Svindland A, Fosså S (2012)
Does a surgeon's annual radical prostatectomy volume predict the risk of positive surgical margins and urinary incontinence at one-year follow-up? Findings from a prospective national study
Scand J Urol, 47 (2), 92-100
DOI 10.3109/00365599.2012.707684, PubMed 22860630

Stensvold A, Dahl AA, Brennhovd B, Småstuen MC, Fosså SD, Lilleby W, Steinsvik A, Axcrona K, Smeland S (2012)
Bother problems in prostate cancer patients after curative treatment
Urol Oncol, 31 (7), 1067-78
DOI 10.1016/j.urolonc.2011.12.020, PubMed 22341412

Publications 2011

Axcrona K, Vlatkovic L, Hovland J, Brennhovd B, Kongsgaard U, Giercksky KE (2011)
Robot-assisted laparoscopic prostatectomy in a 68-year-old patient with previous heart transplantation and pelvic irradiation
J Robot Surg, 6 (1), 81-3
DOI 10.1007/s11701-011-0270-y, PubMed 22408687

Dimmen M, Vlatkovic L, Hole KH, Nesland JM, Brennhovd B, Axcrona K (2011)
Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies
BJU Int, 110 (2 Pt 2), E69-75
DOI 10.1111/j.1464-410X.2011.10759.x, PubMed 22093091

Ma Y, Liang D, Liu J, Axcrona K, Kvalheim G, Stokke T, Nesland JM, Suo Z (2011)
Prostate cancer cell lines under hypoxia exhibit greater stem-like properties
PLoS One, 6 (12), e29170 (Retracted)
DOI 10.1371/journal.pone.0029170, PubMed 22216200

Servoll E, Saeter T, Vlatkovic L, Lund T, Nesland J, Waaler G, Axcrona K, Beisland HO (2011)
Impact of a tertiary Gleason pattern 4 or 5 on clinical failure and mortality after radical prostatectomy for clinically localised prostate cancer
BJU Int, 109 (10), 1489-94
DOI 10.1111/j.1464-410X.2011.10583.x, PubMed 21933333

Steinsvik EA, Axcrona K, Dahl AA, Eri LM, Stensvold A, Fosså SD (2011)
Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother
BJU Int, 109 (9), 1366-74
DOI 10.1111/j.1464-410X.2011.10598.x, PubMed 21999333

Stensvold A, Dahl AA, Brennhovd B, Cvancarova M, Fosså SD, Lilleby W, Axcrona K, Smeland S (2011)
Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones
Prostate, 72 (6), 668-76
DOI 10.1002/pros.21470, PubMed 21809351

Publications 2010

Axcrona K, Brennhovd B, Andersen M, Berner A (2010)
Sarcomatoid squamous cell carcinoma of the penis
Acta Oncol, 49 (1), 128-30
DOI 10.3109/02841860903246565, PubMed 20100148

Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A et al. (2010)
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study
BJU Int, 107 (1), 28-39
DOI 10.1111/j.1464-410X.2010.09648.x, PubMed 20840664

Steinsvik EA, Fosså SD, Axcrona K, Fransson P, Widmark A, Dahl AA (2010)
Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer
J Urol, 184 (2), 525-31
DOI 10.1016/j.juro.2010.04.009, PubMed 20620412

Stensvold A, Dahl AA, Fosså SD, Axcrona K, Lilleby W, Brennhovd B, Smeland S (2010)
Clinicians' use of guidelines as illustrated by curative treatment of prostate cancer at a comprehensive cancer center
Acta Oncol, 50 (3), 408-14
DOI 10.3109/0284186X.2010.492236, PubMed 20586661

Publications 2009

Fosså SD, Egey A, Haukaas SA, Angelsen A, Klepp O, Berge V, Axcrona K, Lilleby W (2009)
[Incorrect about hormone treatment in prostatic cancer]
Tidsskr Nor Laegeforen, 129 (5), 429
DOI 10.4045/tidsskr.08.0649, PubMed 19247406

Hernes E, Kyrdalen A, Kvåle R, Hem E, Klepp O, Axcrona K, Fosså SD (2009)
Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry
BJU Int, 105 (6), 805-11; discussion 811
DOI 10.1111/j.1464-410X.2009.08834.x, PubMed 19735258

Publications 2007

Axcrona K, Brennhovd B, Alfsen GC, Giercksky KE, Warloe T (2007)
Photodynamic therapy with methyl aminolevulinate for atypial carcinoma in situ of the penis
Scand J Urol Nephrol, 41 (6), 507-10
DOI 10.1080/00365590701428590, PubMed 17853049

Lilleby W, Axcrona K, Alfsen GC, Urnes T, Hole KH (2007)
Diagnosis and treatment of primary signet-ring cell carcinoma of the prostate
Acta Oncol, 46 (8), 1195-7
DOI 10.1080/02841860701367886, PubMed 17851841

Publications 2006

Brennhovd B, Johnsrud K, Berner A, Bogsrud T, Waehre H, Giercksky KE, Axcrona K (2006)
Sentinel node procedure in low-stage/low-grade penile carcinomas
Scand J Urol Nephrol, 40 (3), 204-7
DOI 10.1080/00365590600589971, PubMed 16809260

Publications 2002

Frick IM, Axcrona K, Härdig Y, Tapper H, Gustafsson L, Kellner R, Leanderson T, Björck L (2002)
Uptake and intracellular transportation of a bacterial surface protein in lymphoid cells
Mol Microbiol, 44 (4), 917-34
DOI 10.1046/j.1365-2958.2002.02931.x, PubMed 12010489

Frick IM, Bjørck L, Axcrona K, Hardig Y, Tapper H, Gustafsson L, Kellner R, Leanderson T (2002)
Uptake and intracellular transportation of a bacterial surface protein in lymphoid cells
In Molecular microbiology, Blackwell Scientific Publications, Oxford, 44(2002)nr 4, s. 917-934
BIBSYS 031261442

Publications 2001

Axcrona K, Iversen BF, Strømsøe K (2001)
Et uvanlig "fall": infarkt i conus spinalis
In Vitenskapelige forhandlinger, Norsk kirurgisk forening., [Oslo], 2001, Abstrakt nr.153
BIBSYS 022015531

Lindgren H, Axcrona K, Leanderson T (2001)
Regulation of transcriptional activity of the murine CD40 ligand promoter in response to signals through TCR and the costimulatory molecules CD28 and CD2
J Immunol, 166 (7), 4578-85
DOI 10.4049/jimmunol.166.7.4578, PubMed 11254715

Lindgren H, Axcrona K, Leanderson T (2001)
Regulation of transcriptional activity of the murine CD40ligand promoter in response to signals through TCR and the costimulatory molecules CD28 and CD2
In Journal of immunology, The Society, Baltimore, 166(2001)7, s. 4578-85
BIBSYS 022073752

Publications 1998

Axcrona K, Akerblad P, Leanderson T (1998)
Phenotypic convergence and divergence of surface immunoglobulin and CD40 signals
Scand J Immunol, 47 (3), 210-7
DOI 10.1046/j.1365-3083.1998.00295.x, PubMed 9519858

Publications 1996

Axcrona K, Gray D, Leanderson T (1996)
Regulation of B cell growth and differentiation via CD21 and CD40
Eur J Immunol, 26 (9), 2203-7
DOI 10.1002/eji.1830260936, PubMed 8814268

Publications 1995

Axcrona K, Björck L, Leanderson T (1995)
Multiple ligand interactions for bacterial immunoglobulin-binding proteins on human and murine cells of the hematopoetic lineage
Scand J Immunol, 42 (3), 359-67
DOI 10.1111/j.1365-3083.1995.tb03668.x, PubMed 7660068